<DOC>
	<DOCNO>NCT00540150</DOCNO>
	<brief_summary>We want examine immunogenicity safety shorten specific immunotherapy contrast standard specific immunotherapy . Therefore , challenge 12 patient 14 week standard specific scheme 22 patient 6 week shorten scheme .</brief_summary>
	<brief_title>Compatibility Immunogenicity Short Specific Immunotherapy ( SIT ) Contrast Classic Specific Immunotherapy</brief_title>
	<detailed_description>see</detailed_description>
	<criteria>informed consent patient and/or parent age &gt; 6 &lt; 18 year bronchial asthma I째 II째 allergy house dustmite age &lt; 6 &gt; 18 year vital capacity &lt; 80 % FEV1 &lt; 70 % pregnancy inhalative systemic steroid use bronchial asthma III째 IV째 heavy exacerbation last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Mite</keyword>
	<keyword>Asthma</keyword>
	<keyword>bronchial provocation</keyword>
	<keyword>SIT</keyword>
	<keyword>specific immunotherapy</keyword>
</DOC>